Cargando…
Utility of the Cerebral Organoid Glioma ‘GLICO’ Model for Screening Applications
Glioblastoma, a grade IV astrocytoma, is regarded as the most aggressive primary brain tumour with an overall median survival of 16.0 months following the standard treatment regimen of surgical resection, followed by radiotherapy and chemotherapy with temozolomide. Despite such intensive treatment,...
Autores principales: | Weth, Freya R., Peng, Lifeng, Paterson, Erin, Tan, Swee T., Gray, Clint |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818141/ https://www.ncbi.nlm.nih.gov/pubmed/36611949 http://dx.doi.org/10.3390/cells12010153 |
Ejemplares similares
-
Cancer Metastasis and Treatment Resistance: Mechanistic Insights and Therapeutic Targeting of Cancer Stem Cells and the Tumor Microenvironment
por: Kilmister, Ethan J., et al.
Publicado: (2022) -
Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study)
por: Toyoshima, Marcos Tadashi Kakitani, et al.
Publicado: (2023) -
Generating Patient-Derived Gliomas within Cerebral Organoids
por: Linkous, Amanda, et al.
Publicado: (2020) -
Maternal Fructose Intake, Programmed Mitochondrial Function and Predisposition to Adult Disease
por: Smith, Erin Vanessa LaRae, et al.
Publicado: (2022) -
GlicoPro, Novel Standardized and Sterile Snail Mucus Extract for Multi-Modulative Ocular Formulations: New Perspective in Dry Eye Disease Management
por: Mencucci, Rita, et al.
Publicado: (2021)